|
12 Companies |
|
15 Products |
|
15 Products |
|
23 Mechanisms of Action |
|
0 Trials |
|
74 News |
|
| 12» |
- | Trial completion: CogAMS: Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy (clinicaltrials.gov) - Feb 26, 2019
P=N/A, N=40, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA) (clinicaltrials.gov) - Nov 5, 2018
P=N/A, N=23, Completed, Sponsor: University of Michigan
Recruiting --> Completed Recruiting --> Completed | Trial completion date: Jul 2019 --> Sep 2018 | Trial primary completion date: Jul 2019 --> Sep 2018
- | Trial completion date, Trial primary completion date: PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA) (clinicaltrials.gov) - Sep 4, 2018
P=N/A, N=26, Recruiting, Sponsor: University of Michigan
Recruiting --> Completed | Trial completion date: Jul 2019 --> Sep 2018 | Trial primary completion date: Jul 2019 --> Sep 2018 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
- | Trial completion, Phase classification: Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes (clinicaltrials.gov) - Feb 26, 2018
P=N/A, N=196, Completed, Sponsor: Maastricht University Medical Center
Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019 Active, not recruiting --> Completed | Phase classification: P1 --> PN/A
- | losartan / Generic mfg., captopril / Generic mfg.
Trial termination: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Jan 25, 2018
P1, N=12, Terminated, Sponsor: Vanderbilt University
Active, not recruiting --> Completed | Phase classification: P1 --> PN/A Completed --> Terminated; Could not enroll enough participants, and lost funding.
- | Trial initiation date: Treatment of Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Oct 13, 2017
P1, N=152, Completed, Sponsor: Vanderbilt University
Completed --> Terminated; Could not enroll enough participants, and lost funding. Initiation date: Jun 2001 --> Jan 2001
- | Trial primary completion date: PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA) (clinicaltrials.gov) - Sep 25, 2017
P=N/A, N=26, Recruiting, Sponsor: University of Michigan
Initiation date: Jun 2001 --> Jan 2001 Trial primary completion date: Sep 2017 --> Jul 2018
- | Trial completion, Trial primary completion date: SEROTAMS: Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study (clinicaltrials.gov) - Aug 4, 2017
P=N/A, N=53, Completed, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Sep 2017 --> Jul 2018 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016
- | losartan / Generic mfg., captopril / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Aug 3, 2017
P1, N=12, Completed, Sponsor: Vanderbilt University
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Dec 2017 --> Mar 2017
- | ACI-7104.056 / AC Immune, PD03A / AFFiRiS
Trial completion: AFF009: Study Assessing Safety and Therapeutic Activity of AFFITOPE (clinicaltrials.gov) - Jun 5, 2017
P1, N=30, Completed, Sponsor: Affiris AG
Recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Dec 2017 --> Mar 2017 Active, not recruiting --> Completed
- | Enrollment open, Enrollment change: PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA) (clinicaltrials.gov) - Mar 6, 2017
P=N/A, N=26, Recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=21 --> 26
- Enrollment change: Magnetic Resonance Spectroscopy in Autonomic Failure (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=6, Terminated, Sponsor: Vanderbilt University
Active, not recruiting --> Recruiting | N=21 --> 26 N=26 --> 6
- losartan / Generic mfg., captopril / Generic mfg.
Phase classification: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Jan 18, 2017
P1, N=16, Recruiting, Sponsor: Vanderbilt University
N=26 --> 6 Phase classification: P=N/A --> P1
- Trial completion, Phase classification, Trial primary completion date: Treatment of Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Jan 18, 2017
P1, N=152, Completed, Sponsor: Vanderbilt University
Phase classification: P=N/A --> P1 Recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial primary completion date: Sep 2017 --> Jan 2017
- Trial completion, Enrollment change, Trial primary completion date: The Autonomic Nervous System and Obesity (clinicaltrials.gov) - Jan 18, 2017
P1, N=128, Completed, Sponsor: Vanderbilt University
Recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial primary completion date: Sep 2017 --> Jan 2017 Active, not recruiting --> Completed | N=288 --> 128 | Trial primary completion date: Oct 2017 --> Jan 2017
- Trial termination: Magnetic Resonance Spectroscopy in Autonomic Failure (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=26, Terminated, Sponsor: Vanderbilt University
Active, not recruiting --> Completed | N=288 --> 128 | Trial primary completion date: Oct 2017 --> Jan 2017 Recruiting --> Terminated; Could not enroll enough participants, and lost funding.
- Phase classification: The Autonomic Nervous System and Obesity (clinicaltrials.gov) - Jan 12, 2017
P1, N=288, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Terminated; Could not enroll enough participants, and lost funding. Phase classification: P1/2 --> P1
- losartan / Generic mfg., captopril / Generic mfg.
Trial primary completion date: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Jan 12, 2017
P=N/A, N=16, Recruiting, Sponsor: Vanderbilt University
Phase classification: P1/2 --> P1 Trial primary completion date: Dec 2016 --> Dec 2017
- Biomarker, Trial completion, Trial primary completion date: Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension (clinicaltrials.gov) - Jan 6, 2017
P=N/A, N=50, Completed, Sponsor: Vanderbilt University Medical Center
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Dec 2016
- | Trial completion: PROMESA: Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach (clinicaltrials.gov) - Dec 29, 2016
P3, N=92, Completed, Sponsor: Dr. Johannes Levin
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Dec 2016 Active, not recruiting --> Completed
- Trial primary completion date: PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA) (clinicaltrials.gov) - Nov 15, 2016
P=N/A, N=21, Active, not recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Sep 2017
- Biomarker, Trial primary completion date: Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=50, Active, not recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Jul 2016 --> Sep 2017 Trial primary completion date: Mar 2016 --> Mar 2017
- Enrollment closed, Enrollment change: PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA) (clinicaltrials.gov) - Jun 2, 2016
P=N/A, N=21, Active, not recruiting, Sponsor: University of Michigan
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Active, not recruiting | N=50 --> 21
- ACI-7104.056 / AC Immune, PD03A / AFFiRiS
Enrollment closed, Trial primary completion date: AFF009: Study Assessing Safety and Therapeutic Activity of AFFITOPE (clinicaltrials.gov) - May 31, 2016
P1, N=30, Active, not recruiting, Sponsor: Affiris AG
Recruiting --> Active, not recruiting | N=50 --> 21 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Apr 2017
- Enrollment closed, Trial primary completion date: The Autonomic Nervous System and Obesity (clinicaltrials.gov) - Apr 28, 2016
P1/2, N=288, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Apr 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Oct 2017
- Trial primary completion date: Magnetic Resonance Spectroscopy in Autonomic Failure (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=26, Recruiting, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Jul 2016 --> Dec 2016
- losartan / Generic mfg., captopril / Generic mfg.
Trial primary completion date: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=16, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion, Enrollment change, Trial primary completion date: Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. (clinicaltrials.gov) - Feb 27, 2016
P2, N=16, Completed, Sponsor: University of Massachusetts, Worcester
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Completed | N=44 --> 16 | Trial primary completion date: Jan 2016 --> Sep 2015
- Trial completion, Preclinical, Trial primary completion date: [F18]-FDDNP: 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism (clinicaltrials.gov) - Feb 4, 2016
P0, N=40, Completed, Sponsor: Fundacion Clinic per a la Recerca Biomédica
Recruiting --> Completed | N=44 --> 16 | Trial primary completion date: Jan 2016 --> Sep 2015 Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Dec 2015
- Trial primary completion date: Treatment of Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Jan 4, 2016
P1/2, N=160, Recruiting, Sponsor: Vanderbilt University
Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Dec 2015 Trial primary completion date: Sep 2016 --> Sep 2017
- | Enrollment closed: PROMESA: Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach (clinicaltrials.gov) - Sep 3, 2015
P3, N=86, Active, not recruiting, Sponsor: Dr. Johannes Levin
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting
- Trial primary completion date: PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA) (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=50, Recruiting, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Jul 2016
- losartan / Generic mfg., captopril / Generic mfg.
Trial primary completion date: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Jun 23, 2015
P=N/A, N=16, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Apr 2015 --> Jun 2016
- | Bystolic (nebivolol) / Menarini, AbbVie
Trial completion: Nebivolol in the Supine Hypertension of Autonomic Failure (clinicaltrials.gov) - May 2, 2015
P=N/A, N=20, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Apr 2015 --> Jun 2016 Active, not recruiting --> Completed
- ||||||| droxidopa / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy (clinicaltrials.gov) - Apr 25, 2015
P3, N=61, Completed, Sponsor: Chelsea Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=450 --> 61 | Trial primary completion date: Sep 2016 --> Feb 2015
- Trial primary completion date: Treatment of Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=160, Recruiting, Sponsor: Vanderbilt University
Active, not recruiting --> Completed | N=450 --> 61 | Trial primary completion date: Sep 2016 --> Feb 2015 Trial primary completion date: Sep 2015 --> Sep 2016
- ||||| droxidopa / Generic mfg.
Enrollment closed: A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy (clinicaltrials.gov) - Feb 12, 2015
P3, N=450, Active, not recruiting, Sponsor: Chelsea Therapeutics
Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Active, not recruiting
- ACI-7104.056 / AC Immune, PD03A / AFFiRiS
Enrollment open: AFF009: Study Assessing Safety and Therapeutic Activity of AFFITOPE (clinicaltrials.gov) - Dec 19, 2014
P1, N=30, Recruiting, Sponsor: Affiris AG
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | ACI-7104.056 / AC Immune, PD03A / AFFiRiS
New P1 trial: AFF009: Study Assessing Safety and Therapeutic Activity of AFFITOPE (clinicaltrials.gov) - Oct 22, 2014
P1, N=30, Not yet recruiting, Sponsor: Affiris AG
- Bystolic (nebivolol) / Menarini, AbbVie
Trial primary completion date: Nebivolol in the Supine Hypertension of Autonomic Failure (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=18, Active, not recruiting, Sponsor: Vanderbilt University
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Jul 2014
- Preclinical, Journal: [F18]-FDDNP: 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism (clinicaltrials.gov) - Aug 12, 2014
P0, N=40, Recruiting, Sponsor: Fundacion Clinic per a la Recerca Biomédica
- Trial primary completion date: Magnetic Resonance Spectroscopy in Autonomic Failure (clinicaltrials.gov) - May 26, 2014
P=N/A, N=26, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2013 --> Jul 2014 Trial primary completion date: Apr 2015 --> Jul 2016
- Trial completion date: Magnetic Resonance Spectroscopy in Autonomic Failure (clinicaltrials.gov) - May 26, 2014
P=N/A, N=26, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Apr 2015 --> Jul 2016 Trial completion date: Apr 2015 --> Jul 2016
- losartan / Generic mfg., captopril / Generic mfg.
Trial primary completion date: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - May 26, 2014
P=N/A, N=16, Recruiting, Sponsor: Vanderbilt University
Trial completion date: Apr 2015 --> Jul 2016 Trial primary completion date: Jan 2015 --> Apr 2015
- losartan / Generic mfg., captopril / Generic mfg.
Trial initiation date: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - May 26, 2014
P=N/A, N=16, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Jan 2015 --> Apr 2015 Initiation date: Jan 2011 --> Apr 2011
- losartan / Generic mfg., captopril / Generic mfg.
Trial completion date: Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - May 26, 2014
P=N/A, N=16, Recruiting, Sponsor: Vanderbilt University
Initiation date: Jan 2011 --> Apr 2011 Trial completion date: Jan 2015 --> Apr 2015
- Trial primary completion date: Treatment of Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - May 1, 2014
P1/2, N=160, Recruiting, Sponsor: Vanderbilt University
Trial completion date: Jan 2015 --> Apr 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- Trial primary completion date: The Autonomic Nervous System and Obesity (clinicaltrials.gov) - May 1, 2014
P1/2, N=288, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Oct 2014 --> Oct 2015
- Trial completion date: Treatment of Supine Hypertension in Autonomic Failure (clinicaltrials.gov) - May 1, 2014
P1/2, N=160, Recruiting, Sponsor: Vanderbilt University
Trial primary completion date: Oct 2014 --> Oct 2015 Trial completion date: Sep 2014 --> Sep 2016
- Trial completion date: The Autonomic Nervous System and Obesity (clinicaltrials.gov) - May 1, 2014
P1/2, N=288, Recruiting, Sponsor: Vanderbilt University
Trial completion date: Sep 2014 --> Sep 2016 Trial completion date: Oct 2014 --> Oct 2016